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Abstract
Purpose Since the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has
spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly
increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive
association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further
analyse the influence of long-term ADT on PSMA PET/CT findings.
Methods A retrospective analysis was performed of all 1,704 patients who underwent a 68Ga-PSMA-11 PET/CT scan at our
institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADTwith a
continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current
analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during
ongoing ADT.
Results Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration
42–369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values
decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete
PSA response (≤0.1 ng/ml).
Conclusion Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the
objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before
starting ADT.
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Introduction
The detection of recurrent prostate cancer (PC) has always
been challenging using conventional imaging modalities
such as computed tomography (CT) and magnetic reso-
nance imaging. Consequently, there has been a need for
new imaging tools with improved sensitivity and specific-
ity in diagnosis. In this context, nuclear imaging targeting
prostate-specific membrane antigen (PSMA) has received
increased attention. PSMA is a transmembrane protein
which is overexpressed in the majority of aggressive pros-
tatic adenocarcinomas [1–3]. In May 2011, the PSMA
ligand 68Ga-PSMA-11 was introduced for the clinical im-
aging of PC at our institution. Since then, positron emis-
sion tomography (PET) using 68Ga-PSMA-11 and alterna-
tive PSMA ligands has been regarded as a significant step
forward in the diagnosis of recurrent PC. The first studies
indicated that this novel method is superior to alternative
imaging modalities used for the detection of recurrent PC
[4–6]. Later studies including larger patient cohorts con-
firmed the high sensitivity and specificity of 68Ga-PSMA-
11 PET/CT [7–10].
One of the most important questions in PSMA imaging
concerns the role of androgen deprivation therapy (ADT).
It is known from preclinical experiments that short-term
ADT can quantitatively increase PSMA expression in
castration-sensitive PC cells [11, 12]. This effect was
shown with analogues of the luteinizing hormone-
releasing hormone (LHRH) as well as with antiandrogen
agents such as bicalutamide and enzalutamide. In addition,
Hope et al. demonstrated in one patient, that PSMA ligand
uptake in PC lesions significantly increased within 4 weeks
of ADT with bicalutamide [13]. On the other hand, the
effects of long-term ADT on PSMA expression and tumour
visibility in PSMA ligand PET/CT have not yet been inves-
tigated in detail. Two clinical studies including larger pa-
tient cohorts (n = 317 and 1,007) demonstrated that patients
during ongoing ADT significantly more often had a patho-
logical 68Ga-PSMA-11 PET/CT scan [6, 7]. The authors
considered that this association could have been a result
of either a possible biological impact of ADT (increase of
PSMA expression similar to the findings of the preclinical
experiments with short-term ADT mentioned above) or the
fact that patients with a pathological scan had more ad-
vanced tumour stages which had led to the initiation of
ADT.
The aim of the current evaluation was to directly
analyse the clinical impact of long-term ADT on tumour
visibility and tumour detection on 68Ga-PSMA-11 PET/
CT. To the best knowledge of the authors, no systematic
studies have been published including patients who
were scanned with PSMA ligand PET/CT before and
after starting ADT.
Materials and methods
Patients and inclusion criteria
We retrospectively analysed all 1,704 patients who were
scanned with 68Ga-PSMA-11 PET/CTat our department from
May 2011 to December 2017 to detect PC. Patients who were
referred for PSMA radioligand therapy were excluded from
the analysis (n = 192). Of the remaining patients, 306 were
scanned at least twice, and 25 of these had started ADT be-
tween the two 68Ga-PSMA-11 PET/CT scans. Of these 25
patients, 10 continued ADT and showed a PSA response until
the second PET/CT, and were therefore included in the current
analysis. The other 15 of the 25 patients were excluded from
the analysis due to pausing ADT before the second PET/CT
scan, increasing PSA levels indicating castration resistance or
other additional therapies including chemotherapy. The pro-
cess of patient selection for inclusion is shown in Fig. 1. The
characteristics of the ten patients including the ADT drugs
they received are summarized in Table 1. The patient had
previous radiation therapy of the primary PC 3.5 years before
the first PET scan. The radiation therapy was accompanied by
ADT which was continued until 24 months before the first
PET scan. All patients had been partially analysed in previous
studies investigating different aspects [4–7, 14, 15].
Radiotracer and imaging
68Ga-PSMA-11 was produced and PET/CT scans were per-
formed as previously described [7, 16].
Analysis of images and PC lesions
In a first round, two board-certified specialists in nuclear med-
icine with 13 and >20 years of clinical experience (first and
last author) read all datasets together and resolved any dis-
agreements by consensus. Lesions that were visually consid-
ered as suggestive of PC were counted and analysed with
respect to their localization (local relapses, lymph node, bone
and soft tissue metastases) as well as to their average and
maximum standardized uptake values (SUVmean and
SUVmax) which represent the intensity of PSMA ligand ac-
cumulation in PC lesions. SUV in late images was categorized
as increasing, decreasing or stable with intensity changes of
>10%, <−10% or between −10% and +10%, respectively. In a
second round, two board-certified specialists in nuclear med-
icine and radiology (first and third author) read all datasets
together and analysed the lesions with respect to their volumes
(measured using the ellipsoid method by multiplying the three
perpendicular axes A, B, and C and dividing the result by 2).
Any disagreements were resolved by consensus. The tumour
volumes were also categorized as increasing, decreasing or
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stable with intensity changes of >10%, <−10% or between
−10% and +10%, respectively.
Statistical analysis
Significance of differences between PC lesions before and
after ADT with regard to SUVs (mean and maximum),
lesion size, lesion type (lymph nodes or bone metastases;
local relapses and soft tissue metastases were excluded
due to low numbers), and the SUV to lesion size ratios
were evaluated using a linear mixed model including pa-
tient ID and lesion ID as random factors (package ‘lme4’
of R version 3.4.0 software). Thus, the possible effects of
multiple lesions per patient were accounted for. As most
values showed a somewhat skewed distribution, log-
transformation was applied to all variables before statisti-
cal testing, resulting in approximately normal distribu-
tions. For the transformation, the SUVs of lesions which
were PET-negative (no uptake above local background)
were treated as 0.1. PSA levels and number of lesions
were compared between time points using the paired
two-sided Wilcoxon signed ranks test. A p value of
<0.05 was considered statistically significant.
Results
The average duration of ADT before the second PSMA PET/
CT scan was 229 ± 89 days (range 42–369 days, median
230 days). All patients had at least one lesion characteristic
of PC on the initial PET/CT scan (without ADT). Overall, 31
PC lesions were visible in ten patients on the PET/CT scan
before initiation of ADT. During ongoing and effective ADT,
as demonstrated by a decreasing PSA level, 14 of the 31
lesions (45%) were still visible in eight of the ten patients
(80%) on the second PET/CT scan (Table 1). The lower num-
ber of tumour lesions during ongoing ADT was statistically
significant (p = 0.0199). Amongst all lesions characteristic of
PC, 19 were lymph node metastases (eight still visible during
ongoing ADT), ten were bone metastases (five still visible
during ongoing ADT), one was a soft tissue metastasis (lung,
no longer visible during ongoing ADT), and one was a prima-
ry tumour (also still visible during ongoing ADT). Even
though the overall number of lesions was low, the statistical
analysis showed that lymph node metastases were more likely
to become no longer visible than bone metastases (p =
0.0499).
During ongoing ADT, SUVmean increased in four lesions
(12.9%), decreased in 22 (71%) and remained stable in five
(16.1%; Fig. 2). SUVmax increased in five lesions (16.1%),
decreased in 23 (74.2%) and remained stable in three (9.7%;
Fig. 3). The decrease in both SUVmean and SUVmax was
statistically significant (p < 0.0001). Figures 4, 5 and 6 present
examples of the negative impact of continuous ADT on tu-
mour visibility on PSMA ligand PET/CT.
Between PET-1 (without ADT) and PET-2 (during ongoing
ADT) the SUVmean to tumour volume ratio increased in six
lesions (19.4%) and decreased in 23 (74.2%; Fig. 2). In two
lesions, the ratio was not calculable because of a complete
morphological response to the ADT. The same results were
found for the SUVmax to tumour volume ratio (Fig. 3). The
decrease in the SUV to tumour volume ratio during ongoing
ADT was also statistically significant (p = 0.0009 for
SUVmean and p = 0.0007 for SUVmax).
Between PET-1 (without ADT) and PET-2 (during ongoing
ADT) tumour volume increased in ten lesions (32.3%), de-
creased in 15 (48.4%) and remained unchanged in six
(19.3%). The decrease in tumour volume during ongoing
ADT was statistically significant (p = 0.0015). Of the ten le-
sions that showed an increase in volume, two showed an
Fig. 1 Patient selection flow chart
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Table 1 Characteristics of the ten included patients
Patient
no.
Age
(years)
68Ga-PSMA-11 (MBq) Gleason
score
PSA (ng/ml) Time PET-1
to PET-2
(days)
Treatments
prior to
PET-1
Number of
PC lesions
ADT between
PET-1 and PET-2
PET-1 PET-2 PET-1 PET-2 PET-1 PET-2 Drug Duration
(days)
1 70 119 136 7 13.90 1.20 343 RT 2 1 Bicalutamide and
leuprorelin
323
2 73 194 190 9 313.13 14.00 314 None 2 1 Bicalutamide and
leuprorelin
278
3 70 341 212 8 10.50 1.90 309 RPx, RT 5 4 Leuprorelin 231
4 68 110 282 6 1.69 <0.1 377 RT + ADTa 5 0 Leuprorelin 369
5 68 225 211 9 5.20 0.10 207 RT 1 1 Leuprorelin 177
6 66 313 203 7 13.80 <0.1 270 RT 3 3 Bicalutamide 223
7 64 271 230 9 3.10 0.39 102 RPx 1 1 Bicalutamide 42
8 71 221 259 7 5.60 0.10 196 RPx 6 2 Leuprorelin 184
9 77 195 235 7 3.10 0.10 236 RPx 5 1 Bicalutamide 228
10 57 156 226 8 0.25 0.02 334 RPx, RT 1 0 Triptorelin 235
All patients showed decreasing PSA levels between the first and second PET scan
RT Radiation therapy of the prostate or prostate fossa, RPx radical prostatectomy
a Patient 4 had previous radiation therapy 3.5 years before the first PET scan, accompanied by ADTwhich was continued until 24 months before the first
PET scan
Fig. 2 The majority of PC lesions show clearly decreasing average tracer
uptake (SUVmean, top) and tracer uptake to tumour volume ratios (bottom)
during ongoing ADT. No bars are shown for those lesions that were no
longer visible during ongoing ADT (on PET-2) or for those lesions without
a clear morphological correlate in CT (impossible volume measuring).
SUVmean values for the cut bar (number 3) were 20.3 on PET-1 and
27.2 on PET-2. Lesion allocations: lesions 1 and 2 (patient 1), lesions 3
and 4 (patient 2), lesions 5–9 (patient 3), lesions 10–14 (patient 4), lesion
15 (patient 5), lesions 16–18 (patient 6), lesion 19 (patient 7), lesions 20–25
(patient 8), lesions 26–30 (patient 9) and lesion 31 (patient 10)
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increase in SUVmean (one also with an increase in SUVmax),
two showed stable SUVmean (one also with stable SUVmax)
and six showed decreases in both SUVmean and SUVmax. Of
the 15 lesions that showed a decrease in volume, one showed
increases in both SUVmean and SUVmax, and 14 showed a
decrease in SUVmean and SUVmax. Overall, two lesions
showed an increase in volume and in tracer uptake, six lesions
showed an increase in volume and in tracer uptake and two
lesions showed an increase in volume and stable tracer uptake.
PSA levels showed a significant decrease in all patients (p =
0.0001; Fig. 7). Considering a PSA level of 0.1 ng/ml or lower
as a complete response, six patients, patients 4–6 and 8–10
(Fig. 7) with an ADT duration of 184–369 days (average of
236 days), fulfilled this criterion. In these patients, seven of 21
lesions (33.3%) in four patients were still visible during ongo-
ing ADT (Figs. 8 and 9). A complete imaging response (neg-
ative PSMA PET/CT) was observed in two of the six patients
with a complete PSA response (patients 4 and 10).
Discussion
One of the most important clinical questions in PSMA-based
imaging concerns the role of ADT. It is known from
preclinical research that short-term ADT with LHRH ana-
logues as well as androgen receptor blockers such as
bicalutamide and enzalutamide can quantitatively increase
PSMA expression in PC cells [11–13]. If this could also be
observed in the clinical setting in patients receiving long-term
ADT, it would have a substantial positive impact on PSMA
imaging as well as radioligand therapy with PSMA ligands.
Multivariate analyses including larger patient cohorts with
PSMA ligand PET/CT published so far [6, 7] suggest that
68Ga-PSMA-11 PET/CT significantly more often shows path-
ological findings in patients receiving ADT. All these preclin-
ical and clinical reports have tended to convey the impression
that ADT increases tracer uptake and thereby leads to im-
proved sensitivity of PSMA-11 PET/CT. This impression is
reinforced by the fact that even PSMA ligand PET/CT guide-
lines suggest that ADT does not need to be paused prior to
scanning [17]. However, the results of the current study dem-
onstrate for the first time that long-term and effective ADT
significantly decreases tracer uptake on PSMA ligand PET/
CT: only 45% of the lesions were still visible during ongoing
ADT.
Considering the preclinical data mentioned above, no
principal differences were detected between the
androgen-deprivation agents administered to our patients
Fig. 3 The majority of PC lesions show clearly decreasing maximum tracer uptake (SUVmax, top) and tracer uptake to tumour volume ratios (bottom)
during ongoing ADT. No bars are shown for lesions that were no longer visible during ongoing ADT (on PET-2)
Eur J Nucl Med Mol Imaging (2018) 45:2045–2054 2049
and those agents included in the preclinical studies. In
some of the studies, the dose of ADT was higher than
normal doses administered to patients, though: Evans et
al. [11] administered 10 mg/kg of enzalutamide to mice
(dose in patients usually 160 mg/day), and Hope et al.
[13] administered 10 mg/kg/day of apalutamide to mice
(dose in patients 240 mg/day). On the other hand, Hope
et al. used 50 mg/day of bicalutamide in the single
patient reported, which is in the recommended range
for treatment of PC (50–150 mg/day) [13].
The most significant difference between our patients and
the studies discussed above is the duration of ADT: while the
preclinical studies as well as the single patient of Hope et al.
received ADT for 2–30 days [11–13, 18], our patient cohort
was treated for an average of 229 days. The shortest duration
of ADT in our cohort was 6 weeks (patient 7) which is the
closest to the 4 weeks of ADT in the patient of Hope et al. [13].
Although in patient 7 a significantly negative impact of ADT
Fig. 4 Lymph node metastasis in an example patient (patient 8; yellow
arrows) without ADT (a, b) and during ongoing ADT with a complete
PSA response (c, d) 190 days after the first scan. During ongoing ADT,
both, tracer uptake intensity and tumour volume significantly decreased.
a Fused PET and CT image without ADT. b Maximum intensity
projection image of the PET data without ADT. c Fused PET and CT
image during ongoing ADT. d Maximum intensity projection image of
the PET data during ongoing ADT
Fig. 5 Lymph node metastasis in
an example patient (patient 9)
without ADT (a–c) and during
ongoing ADTwith a complete
PSA response (d–f) 228 days
after the first scan (orange arrow
left ureter). a Low-dose CT image
without ADT. b Fused PET and
CT image without ADT. c
Maximum intensity projection
image of the PET data without
ADT. d–f same as a–c but during
ongoing ADT
Fig. 6 Bone metastasis in an example patient (patient 1; yellow arrows)
without ADT (a, b) and during ongoing ADT (c, d) 323 days after the
first scan. a Fused PET and CT image without ADT. b Maximum
intensity projection image of the PET data without ADT. c Fused PET
and CT image during ongoing ADT. d Maximum intensity projection
image of the PET data during ongoing ADT
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on the results of the PET was shown as well, we strongly
believe that the duration of ADT is a key factor in the impact
of ADT on PSMA expression. ADT of short duration may
increase PSMA expression while long-term ADT probably
has the opposite effect. The latter assumption has been ob-
served in a preclinical study by Liu et al. [18]. However, more
longitudinal clinical studies are necessary to analyse this issue.
The intensity of tracer uptake in relation to lesionvolumewas
also analysed in this study. This represents a volume-
independent estimation of PSMA expression. This analysis fre-
quentlydemonstratedadecrease inuptakeduringongoingADT,
counteracting any remaining assumption that long-term ADT
does not negatively affect PSMA expression on PC cells.
Overall, we assume that long-term androgen deprivation results
in apoptosis of androgen-sensitive PC cells, an effect that was
demonstrated by the 1966 Nobel Prize winner Charles Brenton
Huggins. Ingeneral, theeffect of the reduction in tumourvolume
and the decrease in PSAvalues caused by apoptosis is accompa-
nied by a negative impact on tumour detection by imaging. The
higher probability of a pathological PSMA PET/CTscan in pa-
tients receiving ADT found in previous studies was most likely
caused by bias in the selection of patients with more advanced
tumour stages which would have led to initiation of ADT.
Currently the most accepted indication for PSMA ligand
PET/CT is biochemical relapse of PC. Depending on tumour
spread, tumour detection can guide locoregional approaches or
systemic therapies. In such a setting the highest possible sensi-
tivity is mandatory and physicians as well as patients would
rather accept short-term ADT or possibly pausing ADT to op-
timize the diagnostic accuracy of PSMA ligand PET/CT.
Considering the mainly preclinical data discussed above,
short-term ADT may eventually increase PSMA expression
on PC cells, thereby increasing the sensitivity of PSMA ligand
imaging. The findings of all preclinical studies discussed here
as well as in the single patient of Hope et al. suggest that there is
a functional coupling between PSMA and androgen receptors.
However, these studies do not provide any clinical evidence.
Therefore, further evaluations are necessary to determine if
there is any real clinical coupling between PSMA and androgen
receptors. Furthermore, it is well known that LHRH analogues
cause an increase in the whole metabolic activity of PC cells. In
this context, an increase in uptake of PSMA ligands seems
possible and cannot be excluded. However, LHRH analogues
as well as androgen receptor blockers such as bicalutamide
caused a quantitative increase in PSMA expression in the stud-
ies discussed above [11–13].
Fig. 7 APSA response toADTwas observed in all patients (top). A complete imaging response (negative PSMAPET/CT) was observed in patient 4 and
10 although more patients showed a complete PSA response (BIC bicalutamide, LEU leuprorelin, TRI triptorelin)
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Previous evaluations have shown that about one third of
patients referred for PSMA ligand PET/CTare receiving ADT
[6, 7]. We assume that a proportion of them are referred to
confirm the presence of recurrent disease. However, according
to our results, PSMA PET/CT delineates only a fraction of the
tumour disease in patients receiving long-term ADT with a
continuous PSA response. Therefore, these scans are not suit-
able for subsequent therapy planning. Instead, PSMA ligand
PET/CT in patients receiving ADT can be used for response
assessment. For example, early detection of hormone-resistant
lesions can open up new possibilities for individual treatment
strategies. This suggestion is potentially supported by our re-
sults which showed that in patients with complete PSA remis-
sion, 33% of the lesions were still visible (Figs. 8 and 9). This
implies that ADT can cause some Bcosmetic effects^ on PSA
levels while viable tumour is still present. It may be that the
12.9% of lesions showing an increase in tracer uptake on PET-
2 or those lesions still visible during ongoing ADT despite
(complete or incomplete) PSA remission might correlate with
those cell clones that become castration-resistant first.
A future strategy could be to perform PSMA ligand PET/
CT despite a sufficient PSA response. If the scans show re-
maining viable (PSMA-positive) tumour lesions, ADT could
be augmented by novel androgen signalling inhibitors or
taxanes. Otherwise, ADT could be continued without change.
Such a strategy would refine and individualize the recommen-
dations derived from the CHAARTED, LATITUDE and
STAMPEDE trials, which showed a remarkable survival ben-
efit for primarily metastasized patients by adding therapy dur-
ing the castration-sensitive stage [19–21]. If the critical cell
population, from which future tumour progression is derived,
is characterized by continuing PSMA expression during ongo-
ing ADT, PSMA-based radioligand therapy, which has already
shown remarkable antitumour activity in the last-line setting
[22–26], might also be a powerful therapeutic partner for ADT.
Although controversial from a therapeutic point of
view, pausing long-term ADT could help increase the sen-
sitivity of PSMA ligand PET/CT with the aim of visual-
izing the maximum possible extent of disease. The still-
unanswered question is how long does ADT need to be
paused to increase the sensitivity of PSMA ligand imag-
ing. To our knowledge, no data are available on how long
PC cells need to achieve their natural PSMA status after
termination of ADT or whether discontinuing ADT might
even cause a temporary PSMA rebound. It is also unclear
how PSA status is associated with the degree of PSMA
expression. It is known from preclinical studies that PSA
and PSMA promoters are regulated in an opposite manner
with short-term ADT leading to a decrease in PSA levels
and an increase in PSMA expression [12]. On the other
hand, it remains a matter of speculation if the full PSMA
expression status and therefore the maximum possible tu-
mour visibility on PSMA ligand imaging will be achieved
if PSA levels rise to pre-ADT levels.
Fig. 9 Lymph node metastasis in an example patient (patient 9; yellow
arrows) clearly visible on PET-1 without ADT (a, b) which became
significantly less visible on PET-2 with a complete PSA response to
ADT (c, d). a Fused PET and CT image without ADT. b Maximum
intensity projection image of the PET data without ADT. c Fused PET
and CT image during ongoing ADT. d Maximum intensity projection
image of the PET data during ongoing ADT
Fig. 8 Bone metastasis in an example patient (patient 6; yellow arrows;
lesion 16 in Fig. 2) visible on both PET-1 and PET-2 with similar tracer
uptake despite a complete PSA response (0.01 ng/ml) to ADT (a, b PET-1
without ADT; c, d PET-2 during ongoing ADT 270 days after the first
scan). a Fused PET and CT image without ADT. b Low-dose CT image
without ADT. c Fused PET and CT image during ongoing ADT. d Low-
dose CT image during ongoing ADT
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In six of ten morphologically growing lesions the SUV
decreased during ongoing ADT. This observation demon-
strates that changes in SUV can occur independently of lesion
volume. At least regarding bone metastases, it is known that
their volumes can increase after different therapies despite a
good PSA response. However, this increase in volume is
caused by sclerosis and must not be interpreted as tumour
progression. Consequently, the size of bone metastases was
excluded from the Response Evaluation Criteria In Solid
Tumors (RECIST). According to our experience, we believe
that PSMA ligand uptake in tumour lesions represents a more
accurate therapy response criterion than lesion size.
The limitations of this study include the low number of
patients who could be included in the current analysis despite
a large database of more than 1,700 patients, the wide range of
ADT duration and the retrospective nature of the evaluation.
Currently, patients with biochemical relapse should be re-
ferred for PSMA PET before starting ADT. Future studies are
needed to show the impact of short-term ADT in the clinical
setting as well as of alterations in PSMA expression after
pausing ADT.
Conclusion
Long-term ADT in patients with castration-sensitive PC dem-
onstrated a significant negative impact on tumour detection on
PSMA PET/CT. The majority of PC lesions were no longer
visible in patients receiving effective ADT. These findings
indicate that, in the setting of biochemical relapse, PSMA
PET/CT should preferably be performed prior to starting
ADT, with the aim of visualizing the maximum possible ex-
tent of disease. PSMA PET/CT in patients receiving ADTcan
potentially be used for more precise response assessment than
can be achieved with PSA alone: early detection of isolated
hormone-resistant lesions could change the treatment strategy.
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